Hemostasis with WoundClot Hemostatic Gauze in Orthopedic Oncology Surgery

Ortal Segal
National Unit of Orthopedic Oncology, Israel, Tel: 972-3-6973291; E-mail: ortalse@tlvmc.gov.il

Abstract

In general, because tumors are fairly vascular structures, they're vulnerable to bleed throughout the surgery. Systemic ejets of the tumor and chemotherapy and radiotherapy also contribute to the preponderance for the bleeding [1]. In particular, renal cell and thyroid metastases, with marked neovascularization to ascended areas, frequently hemorrhage considerably during surgery, more so than other forms of osseous metastasis.

60% of spinal metastasis, 40% of benign primary spinal neoplasms, and 85% of all malignant primary spinal neoplasms are hypervascular. Additionally to renal and thyroid metastasis, other samples of highly vascular tumors susceptible to bleeding include breast carcinoma, prostate carcinoma, hemangiomas, aneurysmal bone cysts, melanomas, osteoblastomas, osteosarcomas, and giant cell tumors. Some independent indicators of major bleeding include the procedure type, cancer type, female patients, and co-existing arteria coronaria disease or chronic obstructive pulmonary disease.

A potentially large blood loss significantly complicates surgery for patients with hypervascular tumors. Management of patients undergoing surgery for tumors involving the spine or pelvis is particularly problematic thanks to the potential for enormous and ongoing hemorrhage. Pelvic metastases oien hemorrhage significantly regardless of histological subtype, and should be considered for preoperative embolization, especially when lesions are large.

Embolization involves intentional blockage of a vessel to stop blood flow into that vessel. Preoperative tumor embolization could also be considered so as to stop or reduce large blood loss when operating on a highly vascular tumor. Embolization can facilitate the surgery by reducing intraoperative hemorrhage, permitting better visualization of the surgical field, and facilitating more optimal tumor resection. Furthermore, it can help prevent life-threatening hemorrhage and the need for transfusion, as well as potentially decrease surgical time and related complications [2]. Embolization also can contribute to promoting ischemia within the tumor, resulting in necrosis. A chemotherapeutic medication can be added to the embolic agent, to further enhance its eject.

Notwithstanding the benefits of embolization, there are complications with this procedure. A commonly occurring complication of trans-catheter arterial chemoembolization is 'Post embolization syndrome'. Reported in up to 86% of patients, it involves abdominal pain, nausea, vomiting, and fever for 2-3 days post-surgery. With large hepatic tumors, acute liver failure becomes likely, also as biliary sepsis, gallbladder infarction, and hepatic abscess. Embolization in renal cell carcinoma may result in inadvertent embolization of no target vessels, renal failure, renal abscess, and post-embolization syndrome.

A 2009 study by Moreira, Teixeira et al. examining the treatment of orthopedic metastasis, found an almost 27% incidence of complications; furthermore, the foremost frequent surgical complication was bleeding, followed by superficial infection.

Perioperative blood loss during orthopedic surgery is open treated with antifibrinolytic drugs, which prevent blood clots from breaking down. Some which are commonly used are Tranexamic Acid (TXA) and Epsilon-Aminocaproic Acid (EACA) [7]. Here is a few debates about their use in cancer patients, however, thanks to the frequent hypercoagulability present during this population. Aprotinin, another such drug, had demonstrated some initial blood loss decrease also but was far away from the marketplace for causing kidney failure.

Tranexamic acid reduces blood loss and therefore the need for intraoperative transfusion in spine cancer patients. However, it can't be used if the patient is hypersensitive thereto, or if there's a subarachnoid hemorrhage.

On the opposite hand, a significant postoperative complication may be a venous thromboembolism. Perioperative thrombotic complications are a serious explanation for morbidity and mortality, occurring in up to 53% of cases counting on the sort of surgery and comorbidities present.

Here are numerous pharmacological agents that provide thromboprophylaxis, including warfarin, low-dose heparin, low molecular-weight-heparins, and aspirin.

Comorbidities also play a big role. Nearly one-quarter of patients within the aging population who undergo orthopedic surgery have concomitant arteria coronaria disease. It's documented and accepted that arteria coronaria disease may be a risk factor for thrombosis and bleeding complications; cancer also features a similar role as a risk factor. It might be valuable to possess a hemostatic agent that would be used no matter any comorbidities.
Patients further compromised by cancer also are at increased risk for complications involving both thrombosis and bleeding. His possible advantage of decreasing thrombotic events with antiplatelet therapy has got to be weighed against the upper chance of perioperative hemorrhage. An optimal solution would be an eject hemostat that halts bleeding without increasing the potential for thrombosis.

**Biography**

It have more than 15 years of experience in Medical and Pharma as well as other industries in issue.